Epidemiology and management of kawasaki disease

Drugs

Volumn 72, Issue 8, 2012, Pages 1029-1038

  Luca, Nadia J C ^a,b   Yeung, Rae S M ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Abciximab; Anticoagulants; Antiplatelets; Aspirin; Ciclosporin; Corticosteroids; Cyclophosphamide; Haemophagocytic lymphohistiocytosis; Heparin; Immune globulin; Immunosuppressants; Mucocutaneous lymph node syndrome; Myocarditis; Systemic vasculitis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; ETANERCEPT; HEPARIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHYLPREDNISOLONE; PREDNISONE; SALICYLIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ULINASTATIN; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASIA; CORONARY ARTERY ANEURYSM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; ETHNICITY; EUROPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MACROPHAGE ACTIVATION SYNDROME; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYOCARDITIS; NORTH AMERICA; OUTCOME ASSESSMENT; PACIFIC ISLANDS; RISK FACTOR; SEX RATIO; SHOCK; SINGLE DRUG DOSE; THROMBOCYTE ACTIVATION; THROMBOCYTOSIS; THROMBUS;

ANIMALS; CHILD; DISEASE MANAGEMENT; FEMALE; HUMANS; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84861419805     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11631440-000000000-00000     Document Type: Article

References (56)

1. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004 Oct 26; 110 (17): 2747-71 (Pubitemid 39453026)
2. Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006 Jul; 65 (7): 936-41
3. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children [in Japanese]. Arerugi 1967 Mar; 16 (3): 178-222
4. Lin YT, Manlhiot C, Ching JC, et al. Repeated systematic surveillance of Kawasaki disease in Ontario from 1995 to 2006. Pediatr Int 2010 Oct; 52 (5): 699-706
5. Holman RC, Belay ED, Christensen KY, et al. Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007. Pediatr Infect Dis J 2010 Jun; 29 (6): 483-8
6. Holman RC, Christensen KY, Belay ED, et al. Racial/ethnic differences in the incidence of Kawasaki syndrome among children in Hawaii. Hawaii Med J 2010 Aug; 69 (8): 194-7
7. Breunis WB. Inflammation @ the heart of Kawasaki disease: immunogenetic studies on etiology, pathophysiology and treatment effect [dissertation]. Amsterdam: University of Amsterdam, 2010
8. Fischer TK, Holman RC, Yorita KL, et al. Kawasaki syndrome in Denmark. Pediatr Infect Dis J 2007 May; 26 (5): 411-5 (Pubitemid 46789322)
9. Harnden A, Mayon-White R, Perera R, et al. Kawasaki disease in England: ethnicity, deprivation, and respiratory pathogens. Pediatr Infect Dis J 2009 Jan; 28 (1): 21-4
10. Nakamura Y, Yashiro M, Uehara R, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2007-2008 nationwide survey. J Epidemiol 2010; 20 (4): 302-7
11. Park YW, Han JW, Hong YM, et al. Epidemiological features of Kawasaki disease in Korea, 2006-2008. Pediatr Int 2011 Feb; 53 (1): 36-9
12. Huang WC, Huang LM, Chang IS, et al. Epidemiologic features of Kawasaki disease in Taiwan, 2003-2006. Pediatrics 2009 Mar; 123 (3): e401-5
13. Ng YM, Sung RY, So LY, et al. Kawasaki disease in Hong Kong, 1994 to 2000. Hong Kong Med J 2005 Oct; 11 (5): 331-5 (Pubitemid 41499550)
14. Du ZD, Zhao D, Du J, et al. Epidemiologic study on Kawasaki disease in Beijing from 2000 through 2004. Pediatr Infect Dis J 2007 May; 26 (5): 449-51 (Pubitemid 46789331)
15. Heaton P, Wilson N, Nicholson R, et al. Kawasaki disease in New Zealand. J Paediatr Child Health 2006 Apr; 42 (4): 184-90
16. Royle JA, Williams K, Elliott E, et al. Kawasaki disease in Australia, 1993-95. Arch Dis Child 1998 Jan; 78 (1): 33-9
17. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004 Dec; 114 (6): 1708-33 (Pubitemid 41754943)
18. Sudo D, Monobe Y, Yashiro M, et al. Case-control study of giant coronary aneurysms due to Kawasaki disease: the 19th nationwide survey. Pediatr Int 2010 Oct; 52 (5): 790-4
19. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979 Feb; 63 (2): 175-9 (Pubitemid 9083134)
20. Baumer JH, Love SJ, Gupta A, et al. Salicylate for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2006; (4): CD004175
21. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa) B kinase-beta. Nature 1998 Nov 5; 396 (6706): 77-80 (Pubitemid 28520452)
22. Ichida F, Fatica NS, Engle MA, et al. Coronary artery involvement in Kawasaki syndrome in Manhattan, New York: risk factors and role of aspirin. Pediatrics 1987 Dec; 80 (6): 828-35 (Pubitemid 18020319)
23. Furusho K, Sato K, Soeda T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1983 Dec 10; 2 (8363): 1359 (Pubitemid 14245042)
24. Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984 Nov 10; 2 (8411): 1055-8 (Pubitemid 15211522)
25. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986 Aug 7; 315 (6): 341-7 (Pubitemid 16060087)
26. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991 Jun 6; 324 (23): 1633-9
27. Oates-Whitehead RM, Baumer JH, Haines L, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2003; (4): CD004000
28. Leung DY. The immunologic effects of IVIG in Kawasaki disease. Int Rev Immunol 1989; 5 (2): 197-202
29. Lau AC, Duong TT, Ito S, et al. Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease. Arthritis Rheum 2009 Jul; 60 (7): 2131-41
30. Williams RV, Wilke VM, Tani LY, et al. Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics 2002 Jan; 109 (1): E4
31. McCandless RT,Minich LL, Tani LY, et al. Does abciximab promote coronary artery remodeling in patients with Kawasaki disease?AmJ Cardiol 2010 Jun 1; 105 (11): 1625-8
32. Ashouri N, Takahashi M, Dorey F, et al. Risk factors for nonresponse to therapy in Kawasaki disease. J Pediatr 2008 Sep; 153 (3): 365-8
33. Sundel RP, Baker AL, Fulton DR, et al. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003 Jun; 142 (6): 611-6 (Pubitemid 36737160)
34. Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007 Feb 15; 356 (7): 663-75
35. Hashino K, Ishii M, Iemura M, et al. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001 Jun; 43 (3): 211-7 (Pubitemid 32640933)
36. Ogata S, Bando Y, Kimura S, et al. The strategy of immune globulin resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. J Cardiol 2009 Feb; 53 (1): 15-9
37. Furukawa T, Kishiro M, Akimoto K, et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child 2008 Feb; 93 (2): 142-6 (Pubitemid 351204755)
38. Hui-Yuen JS, Duong TT, Yeung RS. TNF-alpha is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J Immunol 2006 May 15; 176 (10): 6294-301
39. Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005 May; 146 (5): 662-7 (Pubitemid 40616253)
40. Burns JC, Best BM, Mejias A, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008 Dec; 153 (6): 833-8
41. Son MB, Gauvreau K, Burns JC, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr 2011 Apr; 158 (4): 644-9
42. Hirono K, Kemmotsu Y, Wittkowski H, et al. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr Res 2009 Jun; 65 (6): 696-701
43. Choueiter NF, Olson AK, Shen DD, et al. Prospective openlabel trial of etanercept as adjunctive therapy for kawasaki disease. J Pediatr 2010 Dec; 157 (6): 960-6.e1
44. Portman MA, Olson A, Soriano B, et al. Etanercept as adjunctive treatment for acute Kawasaki disease: study design and rationale. Am Heart J 2011 Mar; 161 (3): 494-9
45. Benseler SM, McCrindle BW, Silverman ED, et al. Infections and Kawasaki disease: implications for coronary artery outcome. Pediatrics 2005 Dec; 116 (6): e760-6 (Pubitemid 46061096)
46. Suzuki H, Terai M, Hamada H, et al. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J 2011 Oct; 30 (10): 871-6
47. Wallace CA, French JW, Kahn SJ, et al. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000 Jun; 105 (6): E78
48. Uehara R, Yashiro M, Oki I, et al. Re-treatment regimens for acute stage of Kawasaki disease patients who failed to respond to initial intravenous immunoglobulin therapy: analysis from the 17th nationwide survey. Pediatr Int 2007 Aug; 49 (4): 427-30 (Pubitemid 46961843)
49. Kanegaye JT, Wilder MS, Molkara D, et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics 2009 May; 123 (5): e783-9
50. Newburger JW, Sanders SP, Burns JC, et al. Left ventricular contractility and function in Kawasaki syndrome: effect of intravenous gamma-globulin. Circulation 1989 Jun; 79 (6): 1237-46 (Pubitemid 19155758)
51. Latino GA, Manlhiot C, Yeung RS, et al. Macrophage activation syndrome in the acute phase of Kawasaki disease. J Pediatr Hematol Oncol 2010 Oct; 32 (7): 527-31
52. Muise A, Tallett SE, Silverman ED. Are children with Kawasaki disease and prolonged fever at risk for macrophage activation syndrome? Pediatrics 2003 Dec; 112 (6 Pt 1): e495
53. Titze U, Janka G, Schneider EM, et al. Hemophagocytic lymphohistiocytosis and Kawasaki disease: combined manifestation and differential diagnosis. Pediatr Blood Cancer 2009 Sep; 53 (3): 493-5
54. Chen Y, Shang S, Zhang C, et al. Hemophagocytic lymphohistiocytosis at initiation of kawasaki disease and their differential diagnosis. Pediatr Hematol Oncol 2010 Apr; 27 (3): 244-9
55. Kim HK, Kim HG, Cho SJ, et al. Clinical characteristics of hemophagocytic lymphohistiocytosis related to Kawasaki disease. Pediatr Hematol Oncol 2011 Apr; 28 (3): 230-6
56. Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007 Feb; 48 (2): 124-31 (Pubitemid 44958267)